Funded Biotechnology Startups in Paris
The 48 Paris-based biotechnology companies in this listing closed funding rounds between May 2020 and October 2025, with EVerZom's $12M Series A in October…
The 48 Paris-based biotechnology companies in this listing closed funding rounds between May 2020 and October 2025, with EVerZom's $12M Series A in October 2025 as the most recent. Series A is the most represented labeled stage — 12 rounds in total — spanning Genomines ($45M, September 2025), Coave Therapeutics ($33M, January 2025), and Corteria Pharmaceuticals ($70M, September 2023), among others. The three largest disclosed rounds belong to Cellectis ($80M, November 2023), SparingVision ($75M, Series B, September 2022), and HiFiBiO ($75M, June 2021).
All 12 rounds closed in 2025 fall below $50M, with most under $20M — a step down from the $54M–$80M closes seen in 2021–2023. Therapeutic focus is diverse: gene and cell therapy (Coave Therapeutics, Eligo Bioscience, Eyevensys), genomics tools (Depixus, WhiteLab Genomics, Genomines), oncology (Cellectis, Oncovita), microbiome (ENTEROME), and food biotechnology (GOURMEY, Faircraft). Four rounds list undisclosed amounts, including Inotrem and Smart Immune.
Most recent rounds
48 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Paris biotechnology companies in this listing?
The three largest are Cellectis at $80M (Series Unknown, November 2023), SparingVision at $75M (Series B, September 2022), and HiFiBiO at $75M (June 2021). Corteria Pharmaceuticals raised $70M in a Series A in September 2023, and TISSIUM closed a Series D at $54M in May 2023.
How much Paris biotech funding activity appears in 2025?
Twelve companies closed rounds in 2025, ranging from Biophytis and Coave Therapeutics in January through EVerZom's $12M Series A in October. Every 2025 round falls below $50M, with only Genomines ($45M, September 2025) and Coave Therapeutics ($33M, January 2025) exceeding $25M — a notable step down from the $54M–$80M closes recorded in 2021–2023.
Which funding stages appear most frequently?
Series A is the most common labeled stage, covering 12 rounds including Genomines, Coave Therapeutics, Faircraft, Corteria Pharmaceuticals, Core Biogenesis, DAMAE Medical, Depixus, Meiogenix, and Rarecells. A large share of rounds — particularly from 2023 onward — carry a 'Series Unknown' classification, which limits direct stage-by-stage comparison.
Are there any companies at later funding stages?
TISSIUM is the only Series D in the dataset ($54M, May 2023). Series B rounds include SparingVision ($75M), EG 427 ($28M), PathoQuest ($17M), Eyevensys ($12M), CarThera ($5M), and Pili ($5M). Abivax raised $49M in Post-IPO Equity in September 2022, the only post-IPO round listed.
What therapeutic and scientific sub-sectors do these companies cover?
The dataset spans gene and cell therapy (Coave Therapeutics, Eligo Bioscience, Eyevensys, SparingVision), genomics tools (Depixus, WhiteLab Genomics, Genomines), oncology (Cellectis, Oncovita), gut microbiome (ENTEROME), rare disease (Vivet Therapeutics), and food biotechnology (GOURMEY, Faircraft). This spread reflects the range of Paris's Île-de-France research infrastructure rather than a single dominant focus.
How many rounds have undisclosed amounts, and what is the smallest disclosed round?
Four rounds list undisclosed amounts: PresentID (December 2023), Inotrem (November 2023), Smart Immune (March 2023), and Unither Pharmaceuticals (October 2022). The smallest disclosed amount in the listing is Stimunity's $900K close in May 2020, followed by Neovacs at $1M (May 2025) and GenSight Biologics at $580K (July 2025).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.